The Lonza Board of Directors announced the nomination of Stephen Fry as an Independent Member of the Board, with his election scheduled for the Lonza Group Annual General Meeting in May 2026. Subject to his election, Fry will also be appointed to both the People and Governance Committee and the Audit and Compliance Committee, positioning him to influence key aspects of Lonza's corporate oversight and human capital strategy.
Fry brings deep pharmaceutical industry experience to Lonza, having spent more than three decades at Eli Lilly and Company where he held various international, operational and executive leadership roles. His most significant contribution came during his twelve-year tenure as Executive Vice President and Chief Human Resources Officer, where he led large-scale organizational transformation initiatives and helped shape high-performance cultures while navigating the company through periods of significant change. This background in organizational governance, succession planning and people strategy development represents what Chairman Jean-Marc Huet described as "a valuable complementary fit with the capabilities of our other Board members."
The nomination reflects Lonza's strategic focus on strengthening its governance framework and performance culture as the company continues to expand its global operations. As the world's largest contract development and manufacturing organization dedicated to serving the healthcare industry, Lonza works across five continents with approximately 20,000 colleagues who partner with pharma and biotech companies to turn breakthrough innovations into viable therapies. The company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025, according to its financial reporting available at https://www.lonza.com.
Huet emphasized that Fry "will play an important role in helping develop and embed our performance culture," which supports Lonza's ambition "to attract and retain world-leading talent and bring our high-performing teams to the next level." This focus on organizational excellence comes at a time when the contract development and manufacturing sector faces increasing demands for innovation and efficiency in delivering life-saving and life-enhancing treatments to patients worldwide.
Fry's additional role as a Member of the Board of Trustees at the University of Indianapolis further demonstrates his commitment to organizational leadership and governance. His appointment to Lonza's Board comes as the company maintains its headquarters in Basel, Switzerland, with listings on both the SIX Swiss Exchange and Singapore Exchange Securities Trading Limited. The original announcement of Fry's nomination was released through New Media Wire and can be viewed at https://www.newmediawire.com.
